Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Genomic Instability × alectinib × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 29 Neoplasms 5 Lung Neoplasms 4 Neoplasm Metastasis 3 Hematologic Neoplasms 2 Breast Neoplasms 2 Urinary Bladder Neoplasms 1 Thyroid Neoplasms 1 Solid Tumors 1 Sexual Dysfunction, Physiological 1 Sarcoma 1 Rare Tumour 1 Rare Tumor 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Neoplasms by Site 1 Neoplasms by Histologic Type 1 Multiple Endocrine Neoplasia Type 2a 1 Lymphoproliferative Disorders 1 Lymphoma, Large-Cell, Anaplastic 1 Lung Diseases 1 Glioblastoma 1 Genomic Instability 1 Gastrointestinal Neoplasms 1 Eunuchism 1 Erectile Dysfunction 1 Colorectal Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Hepatocellular 1

Interventions

atezolizumab 1 alectinib 1 Vemurafenib 1 Neoadjuvant Therapy 1 Fruit 1 Ado-Trastuzumab Emtansine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02314481 2025-05-23

DARWINII

University College, London

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Genomic Instability

Data powered by HemOnc (CC BY 4.0) Colophon ⚡